Article
Pharmacology & Pharmacy
Keli Wang, Juefang Ding, Xianjing Li, Wenjing Guo, Xingyu Zhu, Yue Su, Luning Sun, Huan Zhou, Li Ding
Summary: This study investigated the drug-drug interactions of Youkenafil. The results showed that Youkenafil was mainly metabolized through CYP3A4/5. Itraconazole increased the concentration of Youkenafil and its metabolite M1, while rifampicin reduced the concentration of Youkenafil. Therefore, co-administration of Youkenafil with potent inhibitors or inducers of CYP3A4/5 should be avoided or carefully monitored.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
(2022)
Article
Infectious Diseases
Tongtong Wang, Yingchu Liu, Chunyu Zhu, Siyuan Yang, Di Yang, Jiang Xiao, Guiju Gao
Summary: This study found that rifampicin does not affect the drug concentrations of efavirenz in patients co-infected with HIV and TB, and virological suppression is good. No dose adjustment of efavirenz is required.
INFECTION AND DRUG RESISTANCE
(2023)
Article
Pharmacology & Pharmacy
Qiao Zhang, Jiejing Kai, You Zhai, Nana Xu, Jianzhong Shentu, Yanyan Zhang, Yanjuan Liang, Yuya Wang, Lihua Wu
Summary: The study found that pretreatment with rifampicin significantly reduced the systemic exposure to fuzuloparib. A single administration of fuzuloparib after multiple oral doses of rifampicin was well-tolerated, without severe adverse events. The exposure of fuzuloparib was dramatically decreased when pretreated with rifampicin, indicating that strong CYP3A4 inducers should be avoided during fuzuloparib treatment.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Jinfu Peng, Guoping Yang, Zhijun Huang
Summary: The study showed that vitamin D deficiency can reduce the response of pravastatin in rats by decreasing liver exposure to the drug and expression of hepatic OATPs.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Microbiology
Aida N. Kawuma, Roeland E. Wasmann, Kelly E. Dooley, Marta Boffito, Gary Maartens, Paolo Denti
Summary: Dolutegravir is recommended as first-line therapy for HIV in low- and middle-income countries. This study analyzed its pharmacokinetics when coadministered with rifampicin and assessed alternative dosing regimens. The results suggest that a once-daily dose of 100 mg of dolutegravir may achieve satisfactory pharmacokinetic target attainment.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Chemistry, Multidisciplinary
Meltem Elitas, Guleser Kalayci Demir, Sumeyra Vural Kaymaz
Summary: Antibiotic resistance is a major global health threat, and improving antibiotic use strategies is urgently needed. This study focuses on the relationship between rifampicin concentration and the growth and killing kinetics of Escherichia coli cells. Through mathematical modeling, the oscillations in the dynamics of rifampicin-exposed E. coli cells were analyzed and a high fitting accuracy was achieved.
Article
Pharmacology & Pharmacy
Lina Keutzer, Huifang You, Ali Farnoud, Joakim Nyberg, Sebastian G. Wicha, Gareth Maher-Edwards, Georgios Vlasakakis, Gita Khalili Moghaddam, Elin M. Svensson, Michael P. Menden, Ulrika S. H. Simonsson
Summary: Pharmacometrics and machine learning are both valuable tools for drug development to understand drug characteristics. Pharmacokinetic/pharmacodynamic analysis using pharmacometrics provides mechanistic insights into biological processes but is time- and labor-intensive. On the other hand, machine learning models are quicker to train but offer less mechanistic insights. Using machine learning predictions of drug PK as input for a PKPD model could greatly accelerate analysis efforts.
Article
Immunology
Kendra K. Radtke, Anneke C. Hesseling, J. L. Winckler, Heather R. Draper, Belen P. Solans, Stephanie Thee, Lubbe Wiesner, Louvina E. van der Laan, Barend Fourie, James Nielsen, H. Simon Schaaf, Radojka M. Savic, Anthony J. Garcia-Prats
Summary: Limited data on the pharmacokinetics and safety of moxifloxacin in children, especially in those with rifampin-resistant tuberculosis, were evaluated in this study. The results suggest that higher doses of moxifloxacin are needed to achieve adult exposures in young children, and further safety assessment is required, particularly when coadministered with other QT-prolonging agents.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Microbiology
Sean Wasserman, Angharad Davis, Cari Stek, Maxwell Chirehwa, Stephani Botha, Remy Daroowala, Marise Bremer, Mpumi Maxebengula, Sonya Koekemoer, Rene Goliath, Amanda Jackson, Thomas Crede, Jonathan Naude, Patryk Szymanski, Yakoob Vallie, Muhammed S. Moosa, Lubbe Wiesner, John Black, Graeme Meintjes, Gary Maartens, Robert J. Wilkinson
Summary: The plasma rifampicin AUC(0-24) was higher after an oral 35-mg/kg dose than with intravenous administration at a 20-mg/kg dose over the first few days of tuberculosis (TB) treatment. The findings support oral rifampicin dosing in future tuberculous meningitis trials.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Respiratory System
Lindsey H. M. te Brake, Veronique de Jager, Kim Narunsky, Naadira Vanker, Elin M. Svensson, Patrick P. J. Phillips, Stephen H. Gillespie, Norbert Heinrich, Michael Hoelscher, Rodney Dawson, Andreas H. Diacon, Rob E. Aamoutse, Martin J. Boeree
Summary: The study evaluated the safety, tolerability, pharmacokinetics, and early bactericidal activity of increasing doses of rifampicin in treatment-naive adult smear-positive patients with tuberculosis. While the 50mg/kg dose showed an increased bactericidal effect, it was not well tolerated, leading to treatment discontinuations, whereas the 40mg/kg dose was well tolerated and selected for further evaluation.
EUROPEAN RESPIRATORY JOURNAL
(2021)
Article
Microbiology
Vianney Tuloup, Mathilde France, Romain Garreau, Nathalie Bleyzac, Laurent Bourguignon, Michel Tod, Sylvain Goutelle
Summary: Rifamycins such as rifampicin and rifabutin are commonly used to treat mycobacterial and staphylococcal infections. Drug-drug interactions caused by rifampicin are more potent than those caused by rifabutin, even with sensitive cytochrome P450 substrates.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Microbiology
Vanessa B. Vogensen, Mathieu S. Bolhuis, Marieke G. G. Sturkenboom, Tjip S. van der Werf, Wiel C. M. de Lange, Richard M. Anthony, Dick van Soolingen, Jan-Willem Alffenaar, Huib A. M. Kerstjens, Onno W. Akkerman
Summary: This retrospective study in a Dutch TB center investigated the impact of rifampicin on moxifloxacin exposure in patients with isoniazid-resistant or -intolerant TB. The study found a clinically significant 39% decrease in moxifloxacin exposure when rifampicin was co-administered, but moxifloxacin dose adjustment may compensate for this drug-drug interaction.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Pharmacology & Pharmacy
Richard Court, Kamunkhwala Gausi, Buyisile Mkhize, Lubbe Wiesner, Catriona Waitt, Helen McIlleron, Gary Maartens, Paolo Denti, Marian Loveday
Summary: This study aimed to explore the effects of pregnancy on the pharmacokinetics of bedaquiline and describe the exposure of bedaquiline in the breast milk of mothers treated for rifampicin-resistant tuberculosis. The results showed lower exposure of bedaquiline in pregnant women and higher concentrations in breast milk. Breastfed infants received doses of bedaquiline equivalent to maternal doses.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Article
Infectious Diseases
T. Goulenok, J. Seurat, A. de La Selle, V. Jullien, V. Leflon-Guibout, N. Grall, F. X. Lescure, R. Lepeule, J. Bertrand, B. Fantin, C. Burdet, A. Lefort
Summary: The study aimed to investigate the pharmacokinetic/pharmacodynamic (PK/PD) interaction between rifampicin and clindamycin in the treatment of staphylococcal osteoarticular infection (SOAI). Results showed that co-administration of rifampicin significantly increased clindamycin clearance and decreased the probability of reaching PK/PD targets. These findings suggest that the use of rifampicin in combination with clindamycin may result in clinical failure, even for fully susceptible strains.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Microbiology
Allan Kengo, Kamunkhwala Gausi, Ruth Nabisere, Joseph Musaazi, Allan Buzibye, Denis Omali, Rob Aarnoutse, Mohammed Lamorde, Kelly E. Dooley, Derek James Sloan, Christine Sekaggya-Wiltshire, Paolo Denti
Summary: This study characterized the pharmacokinetics of rifampicin in Ugandan adults with tuberculosis and HIV, taking different doses and antiretroviral therapy. The results showed a 4.7-fold increase in exposure between high and standard doses, which was lower than what previous reports predicted. The lower bioavailability of the rifampicin-only top-up formulation compared to the fixed-dose combination was identified as the reason.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Neurosciences
Sheng Deng, Xiong Deng, Zhi Song, Xiaofei Xiu, Yi Guo, Jingjing Xiao, Hao Deng
MOLECULAR NEUROBIOLOGY
(2016)
Article
Immunology
Sheng Deng, Hongbo Xu, Jinzhong Yuan, Jingjing Xiao, Lamei Yuan, Xiong Deng, Liping Guan, Anding Zhu, Pengfei Rong, Jianguo Zhang, Hao Deng
INDIAN JOURNAL OF MEDICAL RESEARCH
(2016)
Article
Genetics & Heredity
Han-Xiang Deng, Yong Shi, Yi Yang, Kreshnik B. Ahmeti, Nimrod Miller, Cao Huang, Lijun Cheng, Hong Zhai, Sheng Deng, Karen Nuytemans, Nicola J. Corbett, Myung Jong Kim, Hao Deng, Beisha Tang, Ziquang Yang, Yanming Xu, Piu Chan, Bo Huang, Xiao-Ping Gao, Zhi Song, Zhenhua Liu, Faisal Fecto, Nailah Siddique, Tatiana Foroud, Joseph Jankovic, Bernardino Ghetti, Daniel A. Nicholson, Dimitri Krainc, Onur Melen, Jeffery M. Vance, Margaret A. Pericak-Vance, Yong-Chao Ma, Ali H. Rajput, Teepu Siddique
Article
Neurosciences
Qian Chen, Lamei Yuan, Xiong Deng, Zhijian Yang, Shengwang Zhang, Sheng Deng, Hongwei Lu, Hao Deng
MOLECULAR NEUROBIOLOGY
(2018)
Article
Clinical Neurology
Sheng Deng, Xiong Deng, Lamei Yuan, Zhi Song, Zhijian Yang, Wei Xiong, Hao Deng
ACTA NEUROLOGICA BELGICA
(2015)
Article
Neurosciences
Sheng Deng, Hao Deng, Weidong Le, Hongbo Xu, Huarong Yang, Xiong Deng, Hongwei Lv, Wenjie Xie, Shaihong Zhu, Joseph Jankovic
NEUROSCIENCE LETTERS
(2010)
Article
Neurosciences
Yi Guo, Joseph Jankovic, Zhi Song, Huarong Yang, Wen Zheng, Weidong Le, Xiangqi Tang, Xiong Deng, Yan Yang, Sheng Deng, Ziqiang Luo, Hao Deng
NEUROSCIENCE LETTERS
(2011)
Article
Neurosciences
Yi Guo, Huarong Yang, Xiong Deng, Zhi Song, Zhijian Yang, Wei Xiong, Lamei Yuan, Hongbo Xu, Sheng Deng, Hao Deng
NEUROSCIENCE LETTERS
(2013)
Article
Multidisciplinary Sciences
Fazhong He, Jianquan Luo, Zhiying Luo, Lan Fan, Yijing He, Dingliang Zhu, Jinping Gao, Sheng Deng, Yan Wang, Yuesheng Qian, Honghao Zhou, Xiaoping Chen, Wei Zhang
Article
Multidisciplinary Sciences
Hao Deng, Sheng Deng, Hongbo Xu, Han-Xiang Deng, Yulan Chen, Lamei Yuan, Xiong Deng, Shengbo Yang, Liping Guan, Jianguo Zhang, Hong Yuan, Yi Guo
Article
Biotechnology & Applied Microbiology
Xiaofei Xiu, Jinzhong Yuan, Xiong Deng, Jingjing Xiao, Hongbo Xu, Zhaoyang Zeng, Liping Guan, Fengping Xu, Sheng Deng
BIOMED RESEARCH INTERNATIONAL
(2014)
Article
Behavioral Sciences
Lamei Yuan, Xiong Deng, Zhi Song, Sheng Deng, Wen Zheng, Ping Mao, Hao Deng
BRAIN AND BEHAVIOR
(2018)
Article
Gastroenterology & Hepatology
Heng Xiao, Sheng Deng, Xiong Deng, Shaojuan Gu, Zhijian Yang, Hang Yin, Hao Deng
Article
Chemistry, Medicinal
Cheng-Xian Guo, Sheng Deng, Ji-Ye Yin, Zhao-Qian Liu, Wei Zhang, Hong-Hao Zhou